The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01968928|
Recruitment Status : Unknown
Verified October 2013 by National Taiwan University Hospital.
Recruitment status was: Not yet recruiting
First Posted : October 24, 2013
Last Update Posted : October 28, 2013
|Condition or disease|
|Bladder Urothelial Carcinoma|
Regulation of PKM2 can be a novel target of cancer therapy. Meanwhile, PKM2 may play a critical role in the development of drug resistance and can be a promising target to overcome drug resistance.
In this study, our specific aims are as follows:
- To prove the differentia expression levels of PKM2 in UC cells and drug-resistant UC cells, as well as in human UC tissues and drug-resistant UC tissues.
- To examine the effect of PKM2 regulations（PKM2 siRNA and shikonin）on invasiveness and metastatic ability of UC cells and clarify the role of PKM2 in human UC cells.
- To investigate the combinatory effect of PKM2 regulations（PKM2 siRNA and shikonin）and currently used chemotherapeutic agents (cisplatin，gemcitabine ,doxorubicin). Do PKM2 regulations enhance the cytotoxic effect of chemotherapy and overcome the chemoresistance？
- To further prove the in vitro findings in the nude mice xenograft model。
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||25 participants|
|Target Follow-Up Duration:||1 Day|
|Official Title:||The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2016|
specimens com from drug-resistant bladder urothelial carcinoma patients.
specimens come from normal bladder urothelial carcinoma patients.
specimens come from non-tumoral patients.
- The IHC score [ Time Frame: at the time of surgery ]the IHC scores are acquired by IHC staining and the comparisons between each specimen are determined by IHC scores.
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01968928
|Contact: Kuo-How Huang, M.D., Ph. D||886-2-23123456 ext email@example.com|
|Contact: Chin-Ling Huang||886-2-23123456 ext 65233|
|Department of Urology, National Taiwan University Hospital||Not yet recruiting|
|Taipei, Taiwan, 10002|
|Contact: Kuo-How Huang, M.D.,Ph.D. 886-2-23123456 ext 65952 firstname.lastname@example.org|
|Principal Investigator: Kuo-How Huang, M.D.,Ph.D.|
|Principal Investigator:||Kuo-How Huang, M.D., Ph.D.||Department of Urology, National Taiwan University Hospital, Taipei, Taiwan|